Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2020 Feb 11;10:8. doi: 10.3389/fonc.2020.00008

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2020 Aasebø, Dragomir, Sundström, Mezheyeuski, Edqvist, Eide, Ponten, Pfeiffer, Glimelius and Sorbye.

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

PMC Copyright notice

Median overall survival (OS), progression-free survival (PFS), and response rate if given first-line mono- or combination chemotherapy according to tumor CDX2 status in a population-based Scandinavian cohort of metastatic colorectal cancer. Kaplan–Meier curves were calculated with log-rank test for p-value and univariate Cox regression for HR and 95% CI. (A) Median OS in patients with CDX2 loss. (B) Median OS in patients with CDX2 expressed. (C) Median PFS in patients with CDX2 loss. (D) Median PFS in patients with CDX2 expressed. (E) Response rate (%) after first-line combination chemotherapy according to CDX2 status. n, number; e, events; HR, hazard ratio; CI, confidence interval; CR, complete response; PR, partial response; SD, stable disease; PD, progressive disease.